POST Online Media Lite Edition


Robert Yates to be COO of Ortho-Clinical Diagnostics, Inc

Staff writer |
Washington, DC, USA - June 17, 2014, Washington, DC, USA - Globalalternative asset manager The Carlyle Group announced that Robert Yates will become COO of Ortho-Clinical Diagnostics, Inc. (OCD), subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson, which is expected in mid-2014.

Article continues below

Mr. Yates will also be appointed to OCD’s board of directors. Mr. Yates will join OCD from Merck KGaA where he was President and CEO of EMD/Merck Millipore, its global life sciences division.

Mr. Yates joined Millipore from the diagnostics division of Roche, where he led Roche Applied Science, the life sciences business located in Penzberg, Germany. In that role, he also served as a member of the Diagnostics Executive Committee. He joined Roche in Indianapolis, Indiana in 1988 and held various roles in R&D, Engineering and Operations before being appointed Global Head of Business Development and Licensing in Basel, Switzerland in 2003.


What to read next

Immunodiagnostic Systems CFO left the company
CEO Chris Yates to leave Immunodiagnostic Systems
Agendia names Mark R. Straley as new CEO